Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03176979 · ClinicalTrials.gov registry record · NA
Contrast Enhanced Spectral Mammography With Digital Breast Tomosynthesis For Patients With Newly Diagnosed Breast Cancer
A NA study, sponsored by University of Southern California.
- Completed
- Registry status
- NA
- Development phase
- 43
- Enrollment target
NCT03176979 is a NA study that has completed, run by University of Southern California. The registered enrollment target is 43 participants.
The verdict
NCT03176979, a NA study, has completed, sponsored by University of Southern California.
- COMPLETED
- Registry status
- NA
- Development phase
- 43 participants
- Enrollment target
Study Summary
This pilot clinical trial studies how well contrast enhanced spectral mammography works with digital breast tomosynthesis in imaging patients with newly diagnosed breast cancer. Contrast enhanced spectral mammography uses a special dye that is injected into the veins before mammogram images are taken. Digital breast tomosynthesis uses multiple x-ray pictures to produce a 3-dimensional rendering of the entire breast. Contrast enhanced spectral mammography with digital breast tomosynthesis may highlight areas of concern within the breast in more detail than a standard mammogram and improve the accuracy of tumor size.
Interventions
- OTHER Contrast Agent
- PROCEDURE Digital Tomosynthesis Mammography
- PROCEDURE Dual-Energy Contrast-Enhanced Digital Spectral Mammography
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2017-04-21 |
| Est. Completion | 2021-07-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03176979
The ClinicalTrials.gov registry entry for NCT03176979 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Southern California, which has 617 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Contrast Agent is the first listed.
NCT03176979 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03176979 about?
NCT03176979 is a clinical study titled "Contrast Enhanced Spectral Mammography With Digital Breast Tomosynthesis For Patients With Newly Diagnosed Breast Cancer". This pilot clinical trial studies how well contrast enhanced spectral mammography works with digital breast tomosynthesis in imaging patients with newly diagnosed breast cancer. Contrast enhanced spectral mammography uses a special dye that is injected into the veins before mammogram images are take...
What is the current status of trial NCT03176979?
This trial is currently completed. It is a NA study. The enrollment target is 43 participants. The study started on 2017-04-21. Estimated completion is 2021-07-08.
What interventions are being tested in trial NCT03176979?
The interventions under investigation include: Contrast Agent (OTHER), Digital Tomosynthesis Mammography (PROCEDURE), Dual-Energy Contrast-Enhanced Digital Spectral Mammography (PROCEDURE).
Who is sponsoring clinical trial NCT03176979?
This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.